Purple Biotech PPBT, a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Income investors are drawn to Aristocrats because these stocks have consistently increased their dividends for decades.

Bristol-Myers Squibb (NYSE: BMY) is the kind of stock that potentially has a lot to offer to investors looking for ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Bristol-Myers Squibb's price continues to rise due to a confluence of factors, not the least of which is an earnings surprise in Q3 2024. Learn more on BMY stock here.

It's been a challenging past few years for Bristol Myers Squibb (NYSE: BMY). The company's financial results dipped following ...

Generating thousands of dollars of recurring income can be a great way to make you less reliant on employment income or retirement benefits. While many investors have been focusing on growth stocks ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $58.23 which represents a slight increase of $1.43 or 2.52% from the prior close of $56.8. The stock opened at ...

Research analysts at Zacks Research upped their FY2024 earnings per share estimates for Bristol-Myers Squibb in a research ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $56.80. Don't ...